4basebio Appoints mRNA Pioneer Dr. Jeff Coller to Strategic Advisory Board
核心洞察
4basebio PLC (搜索) has appointed Dr. Jeff Coller, Bloomberg Distinguished Professor of RNA Biology and Therapeutics at Johns Hopkins University, to its Strategic Advisory Board as of June 15, 2026.
Dr. Coller brings over 30 years of expertise in mRNA stability and translation, with seminal discoveries demonstrating that the genetic code determines mRNA stability and transcript fate.
His guidance will support 4basebio's synthetic DNA platform for mRNA synthesis, AAV vector manufacturing, and gene editing applications as the company transitions to a new Cambridge manufacturing facility.
4basebio PLC (搜索) (AIM: 4BB), a Cambridge-based biotechnology company specializing in synthetic DNA manufacturing for next-generation genomic medicines and advanced therapies, announced on June 15, 2026, the appointment of Jeff Coller, Ph.D., to its Strategic Advisory Board (SAB). Dr. Coller, a globally recognized authority in mRNA biology and translation, joins the company at what leadership describes as a pivotal moment in its commercial scale-up.
Dr. Coller serves as the Bloomberg Distinguished Professor of RNA Biology and Therapeutics at The Johns Hopkins University and is the Inaugural Director of the RNA Innovation Center. His laboratory has made seminal discoveries in messenger RNA stability and translation, fundamentally shifting scientific understanding of gene expression by demonstrating that the genetic code acts as a master determinant of mRNA stability and transcript fate.
Strategic Alignment with Manufacturing Scale-Up
The appointment coincides with 4basebio's efforts to scale its synthetic DNA technology across multiple therapeutic modalities, including mRNA synthesis, AAV vector manufacturing, and gene editing applications. Dr. Coller's deep understanding of translation efficiency and mRNA stability is expected to guide the company's strategy to deliver optimized, high-fidelity DNA templates that maximize the therapeutic potential of genetic medicines.
The company is also preparing for its transition to a new state-of-the-art manufacturing facility in Cambridge, a move that underscores its commitment to bridging scientific innovation with commercial-scale bioprocessing solutions.
Leadership Perspectives
Dr. Amy Walker, Chief Executive Officer at 4basebio, emphasized the strategic significance of the appointment: "Jeff's groundbreaking discoveries in mRNA stability and translation are nothing short of transformative for our industry. His vision aligns perfectly with 4basebio's bold mission to dismantle the bottlenecks of traditional manufacturing. With Jeff on our Strategic Advisory Board, we are supercharging our ability to deliver the highest-performing synthetic DNA platforms to our partners — faster, purer, and built for the future of genetic medicine."
Dr. Coller expressed alignment with the company's technological approach, stating: "The future of mRNA therapeutics hinges entirely on the quality and scalability of the starting materials. 4basebio has engineered a truly disruptive approach to synthetic DNA manufacturing that eliminates the legacy challenges of plasmid DNA. I am thrilled to join the Strategic Advisory Board and collaborate with a team that is redefining what is biologically and commercially possible for genetic medicines."
Dr. Coller's Scientific and Industry Credentials
With over 30 years dedicated to the study of mRNA, Dr. Coller's pioneering research has shaped foundational RNA biology and accelerated the development of mRNA therapeutics and vaccines. Beyond his academic roles, he is the co-founder of Tevard Biosciences (搜索), a founding member and Board Director of the Alliance for mRNA Medicines (搜索), and an elected Fellow of the American Association for the Advancement of Science (AAAS). He earned his Ph.D. in Cellular and Molecular Biology from the University of Wisconsin-Madison and completed his postdoctoral fellowship at the Howard Hughes Medical Institute.
About 4basebio's Technology Platform
4basebio employs a proprietary enzymatic DNA synthesis platform to produce GMP-grade synthetic DNA and mRNA. The company's technology is designed to overcome the limitations of plasmid-based systems, offering superior speed, purity, and scalability. Its application-specific DNA constructs are tailored to gene therapies, genome editing, mRNA production, and DNA vaccines, enabling partners to accelerate proof-of-concept studies and reach clinical milestones more efficiently while maintaining safety and quality standards.